Chile Gastric Cancer Treatment Market, By Type (Adenocarcinoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Lymphoma and Others), Stages (Stage III, Stage II, Stage IV, Stage I and Others), Treatment (Chemotherapy, Targeted Therapy, Immune Checkpoint Inhibitors, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Research & Academic Institutes and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others). Industry Trends and Forecast to 2029.
市场分析和见解:智利胃癌治疗市场
智利胃癌治疗市场预计将在2022至2029年的预测期间取得显著增长。 数据桥市场研究分析认为,在2022至2029年的预测期内,市场正在增长,CAGR为7.7%,预计到2029年将达到2375万美元. 肠胃肿瘤、淋巴瘤和腺癌病例增多,增加了对药物和治疗的需求,预计将推动胃癌治疗市场的增长。
胃癌是恶性(癌症)细胞在胃的内脏中形成的一种疾病. 年龄、饮食和胃病会影响胃癌的发展。 胃癌的症状包括消化不良和胃部不适或疼痛.
胃壁由五层组织组成. 从最内层到最外层,胃壁的地层有:黏膜,亚穆可萨,肌肉,亚塞罗萨(接合组织),和serosa. 胃癌开始于黏膜,并随着生长而从外层传播. 胃癌呈多年缓慢发展趋势. 在真正的癌症发作之前,先天性的变化经常会发生在癌症完全发作之前的胃内膜(mucosa). 这些早期的改变很少引起症状,所以经常会不被发现. 癌症在胃的不同部位的发育可引起不同的症状并往往产生不同的结果. 癌症的发病地点也会影响治疗方案。
预计胃癌发病率上升和保健开支增加将促进智利全国市场的增长。
智利胃癌治疗 市场范围和市场规模
智利胃癌治疗市场按类型、阶段、治疗、管理路线、最终用户和分发渠道划分。 不同部门之间的增长有助于你分析特殊的增长领域和接近市场的战略,并确定你的核心应用领域以及目标市场的差异。
- 根据类型,智利胃癌治疗市场被分解为腺癌,胃肠道分泌出腺瘤,卡西诺克瘤,淋巴瘤等. 2021年,由于这种特殊的胃癌在智利的流行程度不断提高,预计adenocarcinoma片段将主导市场.
- 智利胃癌治疗市场按阶段划分为第三阶段、第二阶段、第四阶段、第一阶段等。 2022年,由于这一特定阶段的毒品消费量高,第三阶段部分预计将主导市场.
- 在治疗的基础上,智利胃癌治疗市场分为化疗,定点治疗,免疫检查抑制剂等. 2022年,由于与这种治疗相关的胃癌总体存活率和低复发率,化疗部分预计将占据市场主导地位.
- 根据管理路线,智利胃癌治疗市场分为亲子、口腔等。 2022年,家长部分预计将主导市场,因为它是治疗癌症的最有效方式。 此外,以注射方式提供各种治疗。
- 在最终用户的基础上,智利胃癌治疗市场分为医院、专科诊所、研究和学术机构等。 2022年,预计医院部分将主导市场,因为它为病人提供最好的保健服务。 发达国家和发展中国家的医院由于病人对保健的日益关切,要求接受先进的癌症治疗。
- 根据分配渠道,智利胃癌治疗市场分为医院药房、零售药房等。 2022年,医院药房部分预计将主导市场,因为它们是肿瘤学家推荐的用于胃癌治疗和品牌满意度的各种药物的主要来源.
智利胃癌治疗市场国家一级分析
对智利胃癌治疗市场进行了分析,并按照上述类型、阶段、治疗、管理路线、最终用户和分发渠道提供了市场规模信息。
智利胃癌治疗市场报告所涵盖的国家是智利。
由于药物批准量增加,而且特别是在某些阶段能够作为独立药物进行管理,预计智利的定向产品部门在2022至2029年的预测期内增长率将达到最高水平。
报告的国家部分还介绍了影响市场的因素和国内市场监管的变化,这些因素和变化影响到市场目前和未来的趋势。 新的销售、替代销售、国家人口统计、管制条例和进出口关税等数据点是用来预测个别国家市场情况的一些主要指针。 此外,考虑到智利品牌的存在和可得性,以及由于当地和国内品牌竞争巨大或稀少而面临的挑战,在提供国家数据的预测分析的同时,也考虑了销售渠道的影响。
主要市场参与者为提高对胃癌的认识而开展的越来越多的战略活动正在推动市场增长
智利胃癌治疗市场也为各国在特定市场的增长提供了详细的市场分析。 此外,报告还详细介绍了市场参与者的战略及其地域存在。 现有2020年至2029年期间的数据。
竞争性景观和智利胃癌治疗市场份额分析
智利胃癌治疗市场竞争环境提供了竞争者的详细信息。 详细情况包括公司概况、公司财务、创收、市场潜力、研发投资、新市场举措、生产地点和设施、公司优势和弱点、产品推出、产品试验管道、产品批准、专利、产品宽度和广度、应用优势和技术生命线曲线。 上述数据点仅涉及与智利胃癌治疗市场有关的公司重点
在智利肠道癌治疗市场交易的一些主要公司有:辉瑞公司、Merck KGaA、Celnova Pharma、Teva制药工业有限公司、AstraZenaca、布里斯托尔-迈尔斯·斯基布公司、Sanofi、Laboratorio Varifarma S.A.、Tecnofarma SA.、F. Hoffmann-La Roche有限公司、Biotoscana集团、Megalabs智利SA等。 DBMR分析师了解竞争优势,为每个竞争者分别提供竞争分析.
世界各地的公司也发起了各种合同和协议,从而进一步加快了智利胃癌治疗市场的增长。
比如说,
- 2020年5月,Eli Lily和Company宣布美国食品药品管理局(FDA)批准了CYRAMZA®(RAMUCIRMAB注射,10 mg/mL溶液)与erlotinib结合,用于对患有非小细胞肺癌(NSCLC)并带有上位生长因子受体(EGFR)的一线治疗,19被删除或被exon 21(L858R)突变. 有了这项批准,CYRAMZA现已获得6个FDA批准,用于治疗某些类型的肺癌、肝癌、胃癌和结肠癌。 公司这种新的药品审批方式增加了其销售和市场需求,导致未来的销售量增加.
- 2019年11月,辉瑞股份有限公司宣布其分公司命名为Upjohn与Mylan N.V.合并,并组建了一家名为Viatris的新公司. 公司业务分工与Mylan N.V.的这种组合增加了其产品组合,导致其产品在市场上的需求增加.
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF CHILE GASTRIC CANCER TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS FOR CHILE GASTRIC CANCER TREATMENT MARKET
7 SUMMARY WRITE-UP, CHILE
7.1 OVERVIEW
8 CHILE GASTRIC CANCER TREATMENT MARKET: REGULATORY SCENARIO
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA
9.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING
9.1.3 HEALTH SYSTEM OF CHILE
9.1.4 HIGH PREVALENCE OF OBESITY
9.1.5 RECENT ADVANCEMENTS IN GASTRIC CANCER TREATMENT
9.2 RESTRAINTS
9.2.1 COMMERCIALIZATION OF PHARMACEUTICALS IN CHILE
9.2.2 HIGH COST OF TESTING AND MEDICATIONS
9.2.3 ADVERSE SIDE-EFFECTS OF GASTRIC CANCER TREATMENT
9.3 OPPORTUNITIES
9.3.1 INCREASING DRUG APPROVALS
9.3.2 GOVERNMENT INITIATIVES FOR CANCER CARE
9.3.3 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
9.4 CHALLENGES
9.4.1 CHALLENGE RELATED TO HEALTHCARE PROFESSIONALS
9.4.2 ALTERNATIVE GASTRIC CANCER THERAPIES
10 IMPACT OF COVID-19 PANDEMIC ON CHILE GASTRIC CANCER TREATMENT MARKET
10.1 PRICE IMPACT
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 CHILE GASTRIC CANCER TREATMENT MARKET, BY TYPE
11.1 OVERVIEW
11.2 ADENOCARCINOMA
11.3 GASTROINTESTINAL STROMAL TUMOR
11.4 CARCINOID TUMOR
11.5 LYMPHOMA
11.6 OTHERS
12 CHILE GASTRIC CANCER TREATMENT MARKET, BY STAGES
12.1 OVERVIEW
12.2 STAGE III
12.3 STAGE II
12.4 STAGE IV
12.5 STAGE I
12.6 OTHERS
13 CHILE GASTRIC CANCER TREATMENT MARKET, BY TREATMENT
13.1 OVERVIEW
13.2 CHEMOTHERAPY
13.2.1 FLUOROURACIL
13.2.2 OXALIPLATIN
13.2.3 CISPLATIN
13.2.4 DOCETAXEL
13.2.5 PACLITAXEL
13.2.6 IRINOTECAN
13.2.7 CAPECITABINE
13.2.8 CARBOPLATIN
13.2.9 EPIRUBICIN
13.2.10 OTHERS
13.3 TARGETED THERAPY
13.3.1 MONOCLONAL ANTIBODY THERAPY
13.3.1.1 trastuzumab (herceptin)
13.3.1.2 ramucirumab
13.3.2 MULTIKINASE INHIBITORS
13.3.2.1 Sunitinib
13.3.2.2 Regorafenib
13.4 IMMUNE CHECKPOINT INHIBITORS
13.5 OTHERS
14 CHILE GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 PARENTERAL
14.2.1 INTRAVENOUS
14.2.2 SUBCUTANEOUS
14.2.3 OTHERS
14.3 ORAL
14.3.1 TABLET
14.3.2 CAPSULE
14.3.3 OTHERS
14.4 OTHERS
15 CHILE GASTRIC CANCER TREATMENT MARKET, BY END USERS
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALITY CLINICS
15.4 RESEARCH & ACADEMIC INSTITUTES
15.5 OTHERS
16 CHILE GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.3 RETAIL PHARMACY
16.4 OTHERS
17 CHILE GASTRIC CANCER TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: CHILE GASTRIC CANCER TREATMENT MARKET
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 MERCK KGAA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 PRODUCT PORTFOLIO
19.1.4 RECENT DEVELOPMENTS
19.2 F.HOFFMAN-LA ROCHE LTD
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 PRODUCT PORTFOLIO
19.2.4 RECENT DEVELOPMENT
19.3 TEVA PHARMACEUTICAL INDUSTRIES LTD
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENT
19.4 ASTRAZENECA
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENTS
19.5 SANOFI
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 MEGALABS CHILE S.A.
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BRISTOL-MYERS SQUIBB COMPANY
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 CELNOVA PHARMA
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 GRUPO BIOTOSCANA
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 LABORATORI VARIFARMA S.A.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 NOVARTIS AG
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 PFIZER INC.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 TECNOFARMA S.A.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 CHILE GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 CHILE GASTRIC CANCER TREATMENT MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 3 CHILE GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 4 CHILE CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 5 CHILE TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 6 CHILE MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 7 CHILE MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 8 CHILE GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 9 CHILE PARENTERAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 10 CHILE ORAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 11 CHILE GASTRIC CANCER TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 12 CHILE GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 CHILE GASTRIC CANCER TREATMENT MARKET: SEGMENTATION
FIGURE 2 CHILE GASTRIC CANCER TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 CHILE GASTRIC CANCER TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 CHILE GASTRIC CANCER TREATMENT MARKET: COUNTRY VS REGIONAL MARKET ANALYSIS
FIGURE 5 CHILE GASTRIC CANCER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 CHILE GASTRIC CANCER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 CHILE GASTRIC CANCER TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 8 CHILE GASTRIC CANCER TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 CHILE GASTRIC CANCER TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 CHILE GASTRIC CANCER TREATMENT MARKET: END USER OVERAGE GRID
FIGURE 11 CHILE GASTRIC CANCER TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, ADENOCARCINOMA, AND HIGH PREVALENCE OF OBESITY ARE EXPECTED TO DRIVE THE CHILE GASTRIC CANCER TREATMENT MARKET IN THE FORECAST PERIOD
FIGURE 13 ADENOCARCINOMA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CHILE GASTRIC CANCER TREATMENT MARKET IN 2022 & 2029
FIGURE 14 REGULATORY PROCESS OF DRUGS AND BIOLOGICS APPROVAL IN CHILE
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF CHILE GASTRIC CANCER TREATMENT MARKET
FIGURE 16 CHILE GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2021
FIGURE 17 CHILE GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 18 CHILE GASTRIC CANCER TREATMENT MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 CHILE GASTRIC CANCER TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 CHILE GASTRIC CANCER TREATMENT MARKET: BY STAGES, 2021
FIGURE 21 CHILE GASTRIC CANCER TREATMENT MARKET: BY STAGES, 2020-2029 (USD MILLION)
FIGURE 22 CHILE GASTRIC CANCER TREATMENT MARKET: BY STAGES, CAGR (2022-2029)
FIGURE 23 CHILE GASTRIC CANCER TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 24 CHILE GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, 2021
FIGURE 25 CHILE GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, 2020-2029 (USD MILLION)
FIGURE 26 CHILE GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 27 CHILE GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 28 CHILE GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 29 CHILE GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 30 CHILE GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 31 CHILE GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 32 CHILE GASTRIC CANCER TREATMENT MARKET: BY END USERS 2021
FIGURE 33 CHILE GASTRIC CANCER TREATMENT MARKET: BY END USERS, 2020-2029 (USD MILLION)
FIGURE 34 CHILE GASTRIC CANCER TREATMENT MARKET: BY END USERS, CAGR (2022-2029)
FIGURE 35 CHILE GASTRIC CANCER TREATMENT MARKET: BY END USERS, LIFELINE CURVE
FIGURE 36 CHILE GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 37 CHILE GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 38 CHILE GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 39 CHILE GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 CHILE GASTRIC CANCER TREATMENT MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
